XBRL Proof

XBRL File

Document - Document and Entity Information

Document - Document and Entity Information (USD $)	9 Months Ended
( custom:DocumentAndEntityInformationAbstract [Extension] )
	Sep. 30, 2014	Oct. 8, 2014



Entity Registrant Name	Artventive Medical Group, Inc.
( dei:EntityRegistrantName )
Entity Central Index Key	0001405249
( dei:EntityCentralIndexKey )
Document Type	10-Q
( dei:DocumentType )
Document Period End Date	2014-09-30
( dei:DocumentPeriodEndDate )
Amendment Flag	false
( dei:AmendmentFlag )
Current Fiscal Year End Date	--12-31
( dei:CurrentFiscalYearEndDate )
Is Entity a Well-known Seasoned Issuer?	No
( dei:EntityWellKnownSeasonedIssuer )
Is Entity a Voluntary Filer?	No
( dei:EntityVoluntaryFilers )
Is Entity's Reporting Status Current?	Yes
( dei:EntityCurrentReportingStatus )
Entity Filer Category	Smaller Reporting Company
( dei:EntityFilerCategory )
Entity Public Float
( dei:EntityPublicFloat )
Entity Common Stock, Shares Outstanding		58,506,286
( dei:EntityCommonStockSharesOutstanding )
Document Fiscal Period Focus	Q3
( dei:DocumentFiscalPeriodFocus )
Document Fiscal Year Focus	2014
( dei:DocumentFiscalYearFocus )

(End Document - Document and Entity Information)

Statement - Balance Sheets (Unaudited)

Statement - Balance Sheets (Unaudited) (USD $)
( us-gaap:StatementOfFinancialPositionAbstract )
	Sep. 30, 2014		Dec. 31, 2013





Assets
( us-gaap:AssetsAbstract )
current
( us-gaap:AssetsCurrentAbstract )
Cash and cash equivalents	207,471		1,626,521
( us-gaap:CashAndCashEquivalentsAtCarryingValue )
Accounts receivable	9,450		�
( us-gaap:AccountsReceivableNet )
Prepaid expenses	1,048		9,098
( us-gaap:PrepaidExpenseCurrent )
Inventory	239,754		26,903
( us-gaap:InventoryGross )
Total current assets	457,723		1,662,522
( us-gaap:AssetsCurrent )
PROPERTY, PLANT and equipment
( us-gaap:PropertyPlantAndEquipmentAbstract )
Office equipment	16,380		16,380
( us-gaap:PropertyPlantAndEquipmentOther )
Accumulated depreciation	(4,617	)	(2,303	)
( us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment )
net property, plant and equipment	11,763		14,077
( us-gaap:PropertyPlantAndEquipmentNet )
other assets
( us-gaap:OtherAssetsAbstract )
Deposits	80,497		51,048
( us-gaap:Deposits )
total other assets	80,497		51,048
( us-gaap:OtherAssets )


Total assets	549,983		1,727,647
( us-gaap:Assets )


Liabilities and stockholders’ EQUITY
( us-gaap:LiabilitiesAndStockholdersEquityAbstract )
current LIABILITES
( us-gaap:LiabilitiesCurrentAbstract )
Accounts payable	286,402		272,509
( us-gaap:AccountsPayableCurrent )
Accrued expenses	905,800		585,800
( us-gaap:AccruedLiabilitiesCurrent )
Total CURRENT liabilities	1,192,202		858,309
( us-gaap:LiabilitiesCurrent )


LONG-TERM LIABILITES
( us-gaap:LongTermDebtAbstract )
Notes payable	500,000		�
( us-gaap:NotesPayable )
Total LONG-TERM liabilities	500,000		�
( us-gaap:LongTermDebtNoncurrent )


Total LIABILITIES	1,692,202		858,309
( us-gaap:AccruedLiabilitiesCurrentAndNoncurrent )


stockholders’ EQUITY (deficit)
( us-gaap:StockholdersEquityAbstract )


Common stock, par value $.001, 100,000,000 shares authorized, 58,506,286 and 55,306,286 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively	58,506		55,306
( us-gaap:CommonStockParOrStatedValuePerShare )
Additional paid in capital	11,933,079		9,056,279
( us-gaap:AdditionalPaidInCapital )
Deficit accumulated during the development stage	(13,133,804	)	(8,242,247	)
( us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage )
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)	(1,142,219	)	869,338
( us-gaap:StockholdersEquity )
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	549,983		1,727,647
( us-gaap:LiabilitiesAndStockholdersEquity )

(End Statement - Balance Sheets (Unaudited))

Statement - Balance Sheets (Parenthetical)

Statement - Balance Sheets (Parenthetical) (USD $)
( us-gaap:StatementOfFinancialPositionAbstract )
	Sep. 30, 2014	Dec. 31, 2013





Common stock, par value $.001, authorized	100,000,000	100,000,000
( us-gaap:CommonStockSharesAuthorized )
Common stock, par value $.001, issued and outstanding	58,506,286	55,306,286
( us-gaap:CommonStockSharesIssued )

(End Statement - Balance Sheets (Parenthetical))

Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (USD $)	3 Months Ended				9 Months Ended				92 Months Ended
( us-gaap:IncomeStatementAbstract )
	Sep. 30, 2014		Sep. 30, 2013		Sep. 30, 2014		Sep. 30, 2013		Sep. 30, 2014





revenues	31,865		�		67,500		�		67,500
( us-gaap:Revenues )
cost of goods sold	31,865		�		67,500		�		67,500
( us-gaap:CostOfGoodsSold )
gross profit	�		�		�		�		�
( us-gaap:GrossProfit )
operating expenses
( us-gaap:OperatingExpensesAbstract )
Exploration costs	�		�		�		�		45,533
( us-gaap:ExplorationCosts )
Research and development	1,111,526		434,955		2,770,964		1,317,089		7,787,604
( us-gaap:ResearchAndDevelopmentExpense )
Selling, general and administrative	466,874		393,679		2,118,973		933,723		5,301,231
( us-gaap:SellingGeneralAndAdministrativeExpense )
Depreciation expense	771		583		2,314		1,747		5,133
( us-gaap:Depreciation )
Operating loss before other items and income tax	(1,579,171	)	(829,217	)	(4,892,251	)	(2,252,559	)	(13,139,501	)
( us-gaap:OperatingIncomeLoss )


Other INCOME/(EXPENSE)
( us-gaap:OtherIncomeAndExpensesAbstract )
iNTEREST INCOME	76		82		694		501		5,697
( us-gaap:InterestAndDividendIncomeOperating )
Income tax expense (benefit)	�		�		�		�		�
( us-gaap:IncomeTaxExpenseBenefit )
net loss availAble to common stockholders	(1,579,095	)	(829,135	)	(4,891,557	)	(2,252,058	)	(13,133,804	)
( us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic )
COMPREHENSIVE LOSS FOR THE PERIOD	(1,579,095	)	(829,135	)	(4,891,557	)	(2,252,058	)	(13,133,804	)
( us-gaap:ComprehensiveIncomeNetOfTax )
basic and diluted loss per common share	0		0		0		0
( us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare )
weighted average shares outstanding	58,005,199		52,234,857		56,776,286		51,706,494
( us-gaap:WeightedAverageBasicSharesOutstandingProForma )

(End Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited))

Statement - Consolidated Statements of Cash Flows (Unaudited)

Statement - Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended				92 Months Ended
( us-gaap:StatementOfCashFlowsAbstract )
	Sep. 30, 2014		Sep. 30, 2013		Sep. 30, 2014







cash flow from operating activities
( us-gaap:NetCashProvidedByUsedInOperatingActivitiesAbstract )
Net loss	(4,891,557	)	(2,252,058	)	(13,133,804	)
( us-gaap:NetIncomeLoss )
Adjustments to reconcile net loss to net cash used by operating activities
( us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract )


Non-cash expenses	�		�		60,805
( us-gaap:OtherNoncashIncomeExpense )
Depreciation expense	2,314		1,747		5,133
( us-gaap:DepreciationAndAmortization )
Issuance of common stock and options for services	�		20,169		103,482
( us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities )
Changes IN operating assets and liabilities
( us-gaap:IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract )
Accounts receivable	(9,450	)	�		(9,450	)
( us-gaap:IncreaseDecreaseInAccountsReceivable )
Prepaid expenses	8,050		5,000		(1,048	)
( us-gaap:IncreaseDecreaseInPrepaidExpense )
Inventory	(212,851	)	�		(239,754	)
( us-gaap:IncreaseDecreaseInInventories )
Deposits	(29,449	)	�		(80,497	)
( us-gaap:IncreaseDecreaseInDeposits )
Accounts payable	13,893		183,125		286,402
( us-gaap:IncreaseDecreaseInAccountsPayable )
Payroll taxes payable	�		(42	)	�
( us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities )
Accounts payable – related party	�		�		39,000
( us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties )
Net cash used by operating activities	(5,119,050	)	(2,042,059	)	(12,969,731	)
( us-gaap:NetCashProvidedByUsedInContinuingOperations )
cash flows from investing activities
( us-gaap:NetCashProvidedByUsedInInvestingActivitiesAbstract )
Disposal of equipment	�		�		745
( us-gaap:PropertyPlantAndEquipmentDisposals )
Purchase of equipment	�		(3,551	)	(17,623	)
( us-gaap:PaymentsToAcquirePropertyPlantAndEquipment )
NET CASH used BY INVESTING ACTIVITIES	�		(3,551	)	(16,878	)
( us-gaap:NetCashProvidedByUsedInInvestingActivities )
cash flows from financing activities
( us-gaap:NetCashProvidedByUsedInFinancingActivitiesAbstract )
Issuance of common stock for cash	3,200,000		2,058,000		12,544,080
( us-gaap:ProceedsFromIssuanceOrSaleOfEquity )
Issuance of notes payable	500,000		�		500,000
( us-gaap:ProceedsFromNotesPayable )
Convertible note payable (see Note 4)	�		�		150,000
( us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature )
NET CASH PROVIDED BY FINANCING ACTIVITIES	3,700,000		2,058,000		13,194,080
( us-gaap:NetCashProvidedByUsedInFinancingActivities )
net increase (decrease) in cash and cash equivalents	(1,419,050	)	12,390		207,471
( us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease )


cash, beginning of period	1,626,521		517,831		�
( us-gaap:Cash )
cash, end of period	207,471		530,221		207,471
( us-gaap:Cash )
non-cash investing and financing activities
( us-gaap:CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract )
sTOCK ISSUED UPON CONVERSION OF NOTE PAYABLE	�		�		150,000
( us-gaap:RepaymentsOfConvertibleDebt )
forgiveness OF RELATED PARTY NOTE; APPLIED TO PAID IN CAPITAL	�		�		39,000
( us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt )


ACCRUAL OF STOCK ISSUANCE COST	320,000		205,800		905,800
( us-gaap:PaymentsOfStockIssuanceCosts )

(End Statement - Consolidated Statements of Cash Flows (Unaudited))

Disclosure - Basis of Financial Statement Presentation

Disclosure - Basis of Financial Statement Presentation (USD $)

9 Months Ended

( OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract )

Sep. 30, 2014

Basis of Financial Statement Presentation

BASIS OF FINANCIAL STATEMENT PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared by ArtVentive Medical Group, Inc. “the Company” pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted in accordance with such rules and regulations. The information furnished in the interim condensed financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements. Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim condensed consolidated financial statements be read in conjunction with the Company's audited financial statements and notes thereto included in its Form 10-K filed on March 26, 2014. Operating results for the nine months ended September 30, 2014 are not necessarily indicative of the results to be expected for the fiscal year ended December 31, 2014.

( us-gaap:BasisOfAccounting )

(End Disclosure - Basis of Financial Statement Presentation)

Disclosure - Organization

Disclosure - Organization (USD $)	9 Months Ended
( OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract )
	Sep. 30, 2014



Organization	ORGANIZATION The Company was originally incorporated under the name of Big Bear Resources, Inc. a USA Company registered in the State of Nevada on January 23, 2007. The Company changed its name to Uranium Plus Resources Inc. on March 21, 2008, and following the acquisition of the assets of ArtVentive, Inc. the Company changed its name on January 26, 2010, to ArtVentive Medical Group, Inc. The accounting and reporting policies of the Company conform to accounting principles generally accepted in the United States of America, and the Company’s fiscal year end is December 31. The Company is a medical device corporation, focused on developing, manufacturing and marketing a family of Endoluminal Occlusion Devices (EOS™). Through its innovative, proprietary technology the Company has developed unique minimally invasive occlusion devices and procedures, bringing the current interventional, image guided techniques to a new level of sophistication, potentially resolving significant and unaddressed health issues. The EOS™ device being developed by the Company targets a substantive market demand in several major clinical areas, including women's health, peripheral and neurological vascular disorders, and interventional cardiology procedures. To date, the Company’s activities have been committed to the development of the EOS™, intellectual property, animal studies, human studies, patent filings, and developing a regulatory strategy for initial clinical indications pertinent to European, manufacturing and FDA submissions and approvals, corporate operations and the raising of equity capital. The Company conducted the required human clinical studies during 2011 achieving 100% clinical and procedural success, validating the safety and efficiency of the ArtVentive EOS^TM device. The Company received its CE Mark certification for the ArtVentive EOS™ Peripheral device on May 30, 2013. In 2014 the Company began commercialization and commenced shipping to its European distributors and preparing the foundation for marketing and sales into the USA markets following regulatory approval. On August 3, 2011, the Company incorporated ArtVentive Women’s Health Group, Inc., a wholly owned subsidiary of the Company.
( us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock )

(End Disclosure - Organization)

Disclosure - Significant Accounting Policies

Disclosure - Significant Accounting Policies (USD $)

9 Months Ended

( AccountingPoliciesAbstract )

Sep. 30, 2014

Significant Accounting Policies

SIGNIFICANT ACCOUNTING POLICIES

PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the transactions of the Company and its subsidiary.

All inter-company accounts and transactions have been eliminated in consolidation.

DEVELOPMENT STAGE COMPANY

The Company is considered to be in the development stage as defined in FASC 915-10-05, “Development Stage Entity”. The Company is devoting substantially all of its efforts to the execution of its business plan.

USE OF ESTIMATES

The preparation of the Company’s financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company’s periodic filings with the Securities and Exchange Commission include, where applicable, disclosures of estimates, assumptions, uncertainties and markets that could affect the financial statements and future operations of the Company.

COMMON STOCK ISSUED FOR OTHER THAN CASH

Services purchased and other transactions settled in the Company’s common stock and stock options are recorded at the estimated fair value of the stock issued and options granted if that value is more readily determinable than the fair value of the consideration received.

EARNINGS PER SHARE OF COMMON STOCK

In accordance with accounting guidance now codified as FASB ASC Topic 260, “Earnings per Share,” basic earnings (loss) per share is computed by dividing net income (loss) by weighted average number of shares of common stock outstanding during each period.

Diluted earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period.

The Company had the following potential common stock equivalents at September 30, 2014:

Common stock warrants 5,500,000

Common stock options 105,000

Total common stock equivalents 5,605,000

Since the Company reflected a net loss as of September 30, 2014 and December 31, 2013, the effect of considering any common stock equivalents, if outstanding, would have been anti-dilutive. A separate computation of diluted earnings (loss) per share is not presented.

The following table sets forth the computation of earnings per share:

	For the three months ended September 30, 2014	For the three months ended September 30, 2013	For the nine months ended September 30, 2014	For the nine months ended September 30, 2013
Net income (loss)	(1,579,095)	(829,135)	(4,891,557)	(2,252,058)
Weighted average common shares outstanding	58,005,199	52,234,857	56,776,286	51,706,494
Net (loss) per share	(.03)	(.02)	(.09)	(.04)

PROPERTY AND EQUIPMENT

The Company records property and equipment at cost and uses straight-line depreciation methods.

	Estimated Useful Lives	September 30, 2014	December 31, 2013
Computer equipment Office furniture	5 years 7 years	$ 11,634 4,746	$ 11,634 4,746

Less accumulated depreciation		(4,617)	(2,303)

Net property and equipment		$ 11,763	$ 14,077

ACCOUNTS RECEIVABLE

The Company had accounts receivable of $9,450 and $0 as of September 30, 2014 and December 31, 2013, respectively. These receivables consisted of current trade receivables only and Management has estimated no allowance for bad debts on these amounts.

INVENTORY

The Company has estimated its inventory valued at the lower of cost or market using the first-in, first-out (FIFO) method. As of September 30, 2014 and December 31, 2013, inventory consisted of the following:

	September 30, 2014	December 31, 2013
Inventories
Raw materials	$ 163,509	$ 26,903
Work in Process	52,615	-
Finished goods	23,630	-
Total Inventory	$ 239,754	$ 26,903

As the Company begins its transition from the Research and development phase to production, management has estimated the cost of units sold to be equal to the revenue generated on those units. Other direct costs that may be associated with the production of these units has been reflected in Research and development expenses.

REVENUE RECOGNITION

Sales revenues are generally recognized when an agreement exists and price is determinable, the products are shipped to the customers, and allowance and collectability is reasonable assured.

FOREIGN CURRENCY TRANSLATIONS

The Company’s functional and reporting currency is the US dollar. All transactions initiated in other currencies are translated into US dollars using the exchange rate prevailing on the date of transaction. Monetary assets and liabilities denominated in foreign currencies are translated into the US dollar at the rate of exchange in effect at the balance sheet date. Unrealized exchange gains and losses arising from such transactions are deferred until realization and are included as a separate component of stockholders’ equity (deficit) as a component of other comprehensive income or loss. Upon realization, the amount deferred is recognized in income in the period when it is realized.

The Company recorded an unrealized foreign currency translation gain, totaling $0 for the period from January 23, 2007 (Inception) to September 30, 2014, in accumulated other comprehensive income.

CASH AND CASH EQUIVALENTS

Cash and cash equivalents consist of funds on deposit with banks. The Company has no cash equivalents. The Company had funds on deposit of $207,471 at September 30, 2014.

CONCENTRATION OF RISK

Certain financial instruments, which subject the Company to concentration of credit risk, consist of cash. The Company maintains cash balances at financial institutions, which, from time to time, may exceed Federal Deposit Insurance Corporation insured limits of $250,000. As of September 30, 2014 and December 31, 2013, the Company had $0 and $1,415,194, respectively, in deposits in excess of federally insured limits in its US bank. The Company has not experienced any losses with regard to its bank accounts and believes it is not exposed to any risk of loss on its cash in bank accounts.

( us-gaap:SignificantAccountingPoliciesTextBlock )

(End Disclosure - Significant Accounting Policies)

Disclosure - Long-Term Debt

Disclosure - Long-Term Debt (USD $)

9 Months Ended

( DebtDisclosureAbstract )

Sep. 30, 2014

Long-Term Debt

LONG-TERM DEBT

The details concerning long-term debt for the three months ended September 30, 2014, and the year ended December 31, 2013, follow:

	September 30, 2014	December 31, 2013
Note payable to a private party, with interest at 3.0%, with interest only payments due December 31, 2014 and June 30, 2015, with the balance, interest and principal, due December 31, 2015	$ 250,000	$ -
Note payable to a Private Party, with interest at 3.0%, with interest only payments due December 31, 2014 and June 30, 2015, with the balance, interest and principal, due December 31, 2015	250,000	-
Total	500,000	-
Less current maturities of long-term debt	-	-
Noncurrent maturities of long-term debt	$ 500,000	$ -

The Principal Maturities of Notes Payable, by year, are as follows:

2014	-
2015	$ 500,000
	$ 500,000

( us-gaap:LongTermDebtTextBlock )

(End Disclosure - Long-Term Debt)

Disclosure - Share Capital

Disclosure - Share Capital (USD $)	9 Months Ended
( EquityAbstract )
	Sep. 30, 2014



Share Capital	SHARE CAPITAL Effective April 22, 2008, the Company forward-split its issued capital stock on a ratio of 5.8 shares for each prior share. As a result of this transaction, 11,078,000 shares were issued. Effective February 12, 2010, the Company forward-split its issued capital stock on a ratio of 1.65 a share for each 1 old share. As a result of this transaction 8,442,200 shares were issued. Effective February 19, 2010, 3,767,051 shares were issued in a private placement. Consideration for the issue of additional shares has been charged against additional paid in capital. The forward stock splits adjustments have been reflected retroactively. Effective April 16, 2010, the Board of Directors of the Company authorized issuance of 20,000 shares to the members of its Scientific Board at a deemed value per share of $.90. Effective June 2, 2011, and December 30, 2011, the Board of Directors of the Company authorized issuance of 3,888 and 13,611 shares to the former consultants at a deemed value per share of $.90. Effective June 26, 2012, 200,000 shares were issued in a private placement for the receipt of $200,000. Effective July 5, 2012, the Company’s subscription agreement was amended to include finder’s fee of 10% of the amount raised in the future in the form of shares of restricted common stock. Effective September 12, 2012, 500,000 shares were issued in a private placement for the receipt of $500,000. On October 3, 2012, October 12, 2012, November 5, 2012, and December 12, 2012, 250,000 shares each were issued in a private placement for the total receipt of $1,000,000. Effective February 7, 2013, 500,000 shares were issued in a private placement for the receipt of $500,000. Effective March 5, 2013, 150,000 shares were issued in a private placement for the receipt of $150,000. Effective April 22, 2013, 100,000 shares were issued in a private placement for the receipt of $100,000. Effective June 4, 2013, 308,000 shares were issued in a private placement for the receipt of $308,000. Effective July 16, 2013, 300,000 shares were issued in a private placement for the receipt of $300,000. Effective August 30, 2013, 200,000 shares were issued in a private placement for the receipt of $200,000. Effective September 11, 2013, 200,000 shares were issued in a private placement for the receipt of $200,000. Effective September 22, 2013, 300,000 shares were issued in a private placement for the receipt of $300,000. Effective October 4, 2013, 300,000 shares were issued in a private placement for the receipt of $300,000. Effective November 8, 2013, 400,000 shares were issued in a private placement for the receipt of $400,000. Effective December 2, 2013, 400,000 shares were issued in a private placement for the receipt of $400,000. Effective December 10, 2013, 400,000 shares were issued in a private placement for the receipt of $400,000. Effective December 30, 2013, 400,000 shares were issued in a private placement for the receipt of $400,000. Effective January 7, 2014, 400,000 shares were issued in a private placement for the receipt of $400,000. Effective February 11, 2014, 400,000 shares were issued in a private placement for the receipt of $400,000. Effective March 6, 2014, 300,000 shares were issued in a private placement for the receipt of $300,000. Effective May 23, 2014, 100,000 shares were issued in a private placement for the receipt of $100,000. Effective June 24, 2014, 1,000,000 shares were issued in a private placement for the receipt of $1,000,000. Effective July 23, 2014, 500,000 shares were issued in a private placement for the receipt of $500,000. Effective August 29, 2014, 250,000 shares were issued in a private placement for the receipt of $250,000. Effective September 29, 2014, 150,000 shares were issued in a private placement for the receipt of $150,000. Effective September 30, 2014, 100,000 shares were issued in a private placement for the receipt of $100,000.
( us-gaap:StockholdersEquityNoteDisclosureTextBlock )

(End Disclosure - Share Capital)

Disclosure - Going Concern and Liquidity Considerations

Disclosure - Going Concern and Liquidity Considerations (USD $)	9 Months Ended
( OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract )
	Sep. 30, 2014



Going Concern and Liquidity Considerations	GOING CONCERN AND LIQUIDITY CONSIDERATIONS The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of September 30, 2014, the Company has a working capital deficit of $734,479 and an accumulated deficit of $13,133,804. The Company intends to fund operations through equity financing arrangements, which should be sufficient to fund its capital expenditures, working capital and other cash requirements for the next twelve months. The ability of the Company to emerge from the development stage is dependent upon, among other things, obtaining additional financing to continue operations, research, development and production of its product. In response to these challenges, management intends to raise additional funds through public or private placement offerings. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.
( us-gaap:LiquidityDisclosureTextBlock )

(End Disclosure - Going Concern and Liquidity Considerations)

Disclosure - Recently Issued Accounting Pronouncements

Disclosure - Recently Issued Accounting Pronouncements (USD $)	9 Months Ended
( OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract )
	Sep. 30, 2014



Recently Issued Accounting Pronouncements	recently issued accounting pronouncements Accounting Standards Updates (“ASU”) ASU No. 2014-16 which contain technical corrections to existing guidance or affect guidance to specialized industries or entities were recently issued. These updates have no current applicability to the Company or their effect on the financial statements would not have been significant.
( us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock )

(End Disclosure - Recently Issued Accounting Pronouncements)

Disclosure - Provision for Income Taxes

Disclosure - Provision for Income Taxes (USD $)	9 Months Ended
( IncomeTaxDisclosureAbstract )
	Sep. 30, 2014



Provision for Income Taxes	provision for income taxes The Company recognizes the tax effects of transactions in the year in which such transactions enter into the determination of net income, regardless of when reported for tax purposes. Deferred taxes are provided in the financial statements under ASC Topic 740 to give effect to the resulting temporary differences which may arise from differences in the bases of fixed assets, depreciation methods, allowances, and start-up costs based on the income taxes expected to be payable in future years. Minimal exploration stage deferred tax assets arising as a result of net operating loss carry forwards have been offset completely by a valuation allowance due to the uncertainty of their utilization in future periods. The Company adopted the provisions of ASC Topic 740 Accounting for Uncertainty in Income Taxes, on January 23, 2007 (inception date). As a result of the implementation of ASC 740, the Company recognized no increase in the liability for unrecognized tax benefits. Operating loss carry-forwards generated during the period of January 23, 2007 (date of inception), through September 30, 2014, of approximately $13,030,322 will begin to expire in 2027. Accordingly, deferred tax assets of approximately $5,502,973 related to net operating loss carry-forwards, and $44,332 related to stock-based compensation were offset by the valuation allowance in the same amount. For the nine months ended September 30, 2014 and 2013, the allowance increased by approximately $2,095,543 and $955,821, respectively. The Company has no tax positions at September 30, 2014, or December 31, 2013, for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company had no accruals for interest and penalties since inception. The Company is subject to taxation in the United States and California. As of September 30, 2014, the Company’s tax years for 2011, 2012 and 2013 are subject to examination by the U.S. and California tax authorities. In addition, the 2010 tax year remains subject to examination by California tax authorities.
( us-gaap:IncomeTaxDisclosureTextBlock )

(End Disclosure - Provision for Income Taxes)

Disclosure - Contractual Obligations

Disclosure - Contractual Obligations (USD $)	9 Months Ended
( DebtDisclosureAbstract )
	Sep. 30, 2014



Contractual Obligations	Contractual obligations Effective March 1, 2010, the Company entered into Management Agreements with Dr. Leon Rudakov and H. James Graham. Under the terms of the Employment Agreement with its then Chief Executive Officer (CEO) and Chief Technology Officer (CTO), Dr. Rudakov was compensated with an annual salary of $120,000, plus benefits. As of February 1, 2011, the base salary was amended to $170,000 per annum to reflect his current positions as the President and CTO. The agreement includes other employment benefits. Effective June 1, 2013, the agreement was amended to reflect a term to December 31, 2018, with an annual salary of $250,000 per annum. Under the terms of a consulting Agreement, effective March 1, 2010, Mr. Jim Graham was compensated with annual base fee of $100,000 per annum, plus benefits. As of February 1, 2011, the agreement was amended to reflect Mr. Graham’s current positions of Chief Executive Officer, Chief Financial Officer and Chairman of the Board of Directors to reflect a base annual fee of $180,000 per annum. Effective June 1, 2013, the agreement was amended to reflect a term to December 31, 2018, with an annual fee of $260,000 per annum. Effective September 2013, the Company (“Supplier”) executed revised Amended and Restated Distribution Agreements (the “Agreements”) with its current European Distributors (“Distributors”) in the Netherlands, Germany, Austria, Switzerland and Italy. The Agreements grant the Distributor the exclusive right to offer for sale and sell the EOS Systems in the respective territories covered by each of the Agreements. There is a minimum purchase of products included in each of the Agreements. The new Agreements incorporate a quality agreement provision as a part of the original Distribution Agreement.
( us-gaap:DebtDisclosureTextBlock )

(End Disclosure - Contractual Obligations)

Disclosure - Purchase Agreement

Disclosure - Purchase Agreement (USD $)	9 Months Ended
( HealthCareOrganizationsAbstract )
	Sep. 30, 2014



Purchase Agreement	PURCHASE AGREEMENT On January 8, 2010, the Company entered into an asset purchase agreement with Artventive, Inc. a privately held company. The Company purchased substantially all of the assets of Artventive, Inc., which consisted entirely of patents. The patents were accounted for under SAB Topic 5G using the historical cost basis of zero. The combination was accounted for under ASC 805 as a business combination.
( us-gaap:BusinessAndContractualArrangementsDisclosureTextBlock )

(End Disclosure - Purchase Agreement)

Disclosure - Warrants and Options

Disclosure - Warrants and Options (USD $)

9 Months Ended

( CompensationAndRetirementDisclosureAbstract )

Sep. 30, 2014

Warrants and Options

Warrants and options

During the fiscal year ended December 31, 2013, the Company has granted 4,358,000 warrants to purchase shares of Common Stock which all have a 1 year exercise term, of which 2,300,000 remain outstanding at September 30, 2014. During the nine months ended September 30, 2014, 3,200,000 warrants were issued. The issuance of outstanding warrants is detailed below.

Effective July 16 2013, 300,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year

Effective October 4 2013, 300,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year

Effective October 25, 2013, 400,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year

Effective November 8, 2013, 400,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year

Effective December 2, 2013, 400,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year

Effective December 10, 2013, 400,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year

Effective December 30, 2013, 400,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year

Effective January 7, 2014, 400,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year

Effective February 11, 2014, 400,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year

Effective March 6, 2014, 300,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year

Effective May 23, 2014, 100,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year

Effective June 24, 2014, 1,000,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year

Effective July 23, 2014, 500,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year

Effective August 29, 2014, 250,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year

Effective September 29, 2014, 150,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year

Effective September 30, 2014, 100,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year

The Company valued all warrants utilizing a Black-Scholes option-pricing model and the fair value was recorded in additional paid-in capital.

The following is a summary of the Company’s warrants activity:

	Warrants	Weighted Average Exercise Price
Exercisable – December 31, 2012	1,500,000	$ 1.50
Granted-2013	4,358,000	$ 1.50
Exercised-2013	-	-

Forfeited-2013	(1,500,000)	$ 1.50
Outstanding – December 31, 2013	4,358,000	$ 1.50
Exercisable – December 31, 2013	4,358,000	$ 1.50

	Warrants	Weighted Average Exercise Price
Granted-2014 (at September 30, 2014)	3,200,000	$ 1.50
Exercised-2014 (at September 30, 2014)	-	-
Forfeited-2014 (at September 30, 2014)	(2,058,000)	$ 1.50
Outstanding – September 30, 2014	5,500,000	$ 1.50
Exercisable – September 30, 2014	5,500,000	$ 1.50

Warrants outstanding and exercisable at September 30, 2014 are as follows:

Warrants Outstanding				Warrants Exercisable
	Range of Exercise Price	Number Outstanding	Weighted Average Remaining Contractual Life (in Years)	Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$	1.50	300,000	0.01 years	$	1.50		300,000	$	1.50
$	1.50	400,000	0.06 years	$	1.50		400,000	$	1.50
$	1.50	400,000	0.11 years	$	1.50		400,000	$	1.50
$	1.50	400,000	0.16 years	$	1.50		400,000	$	1.50
$	1.50	400,000	0.18 years	$	1.50		400,000	$	1.50
$	1.50	400,000	0.23 years	$	1.50		400,000	$	1.50
$	1.50	400,000	0.26 years	$	1.50		400,000	$	1.50
$	1.50	400,000	0.35 years	$	1.50		400,000	$	1.50
$	1.50	300,000	0.43 years	$	1.50		300,000	$	1.50
$	1.50	100,000	0.64 years	$	1.50		100,000	$	1.50
$	1.50	1,000,000	0.73 years	$	1.50		1,000,000	$	1.50
$	1.50	500.000	0.81 years	$	1.50		500,000	$	1.50
$	1.50	250.000	0.90 years	$	1.50		250,000	$	1.50
$	1.50	150.000	0.96 years	$	1.50		150,000	$	1.50
$	1.50	100,000	1.00 years	$	1.50		100,000	$	1.50

Effective November 2, 2010 the Board of Directors of the Company granted 50,000 non-statutory stock options to a former consultant at an exercise price of $.001 per share with the vesting date of November 2, 2013 and an expiration date of November 2, 2016.

Effective February 1, 2013 the Board of Directors of the Company granted 20,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with the vesting date of February 1, 2013 and an expiration date of February 1, 2018.

Effective February 1, 2013 the Board of Directors of the Company granted 5,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with the vesting date of February 1 2013 and an expiration date of February 1, 2018.

Effective February 1, 2013 the Board of Directors of the Company granted 10,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with the vesting date of February 1 2013 and an expiration date of February 1, 2018.

Effective March 1, 2013 the Board of Directors of the Company granted 10,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with the vesting date of March 1, 2013 and an expiration date of March 1, 2018.

Effective December 27, 2013 the Board of Directors of the Company granted 10,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with the vesting date of December 27, 2013 and an expiration date of December 27, 2018.

During the period that the options were issued, the Company had no public trading activity for the Company’s common stock. However, the majority shareholder sold in private transactions shares at $.90 per share. In order to value the Company’s options, the Company chose to use the minimum value method, even though the Company is a public company since there was no measurable trading activity. The fair value of the options was recorded in additional paid-in capital.

Options outstanding and exercisable at September 30, 2014 are as follows:

	Options	Weighted Average Exercise Price
Exercisable – December 31, 2012	50,000	$ 0.001
Granted-2013	55,000	$ 1.00
Exercised-2013	-	-
Forfeited-2013	-	-
Outstanding – December 31, 2013	105,000	$ 0.524
Exercisable – December 31, 2013	105,000	$ 0.524
	Options	Weighted Average Exercise Price
Granted-2014 (at September 30, 2014)	-	$ -
Exercised-2014 (at September 30, 2014)	-	-
Forfeited-2014 (at September 30, 2014)	-	$ -
Outstanding – September 30, 2014	105,000	$ 0.524
Exercisable – September 30, 2014	105,000	$ 0.524

Options outstanding and exercisable at September 30, 2014 are as follows:

Options Outstanding							Options Exercisable
	Range of Exercise Price		Number Outstanding		Weighted Average Remaining Contractual Life (in Years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$		0.001		50,000		2.09 years	$	0.001		50,000		$	0.001
$		1.000		35,000		3.34 years	$	1.000		35,000		$	1.000
$		1.000		10,000		3.42 years	$	1.000		10,000		$	1.000
$		1.000		10,000		4.24 years	$	1.000		10,000		$	1.000

( us-gaap:CompensationAndEmployeeBenefitPlansTextBlock )

(End Disclosure - Warrants and Options)

Disclosure - Subsequent Events

Disclosure - Subsequent Events (USD $)	9 Months Ended
( SubsequentEventsAbstract )
	Sep. 30, 2014



Subsequent Events	SUBSEQUENT EVENTS The Company evaluated all events or transactions that occurred after September 30, 2014, up through the date these consolidated financial statements were issued and determined there are no significant events to disclose.
( us-gaap:SubsequentEventsTextBlock )

(End Disclosure - Subsequent Events)

Disclosure - Significant Accounting Policies (Policies)

Disclosure - Significant Accounting Policies (Policies) (USD $)

9 Months Ended

( AccountingPoliciesAbstract )

Sep. 30, 2014

Principles of Consolidation

PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the transactions of the Company and its subsidiary.

All inter-company accounts and transactions have been eliminated in consolidation.

( us-gaap:ConsolidationPolicyTextBlock )

DEVELOPMENT STAGE COMPANY

DEVELOPMENT STAGE COMPANY

( us-gaap:DevelopmentStageEnterpriseGeneralDisclosuresTextBlock )

USE OF ESTIMATES

USE OF ESTIMATES

( us-gaap:UseOfEstimates )

COMMON STOCK ISSUED FOR OTHER THAN CASH

COMMON STOCK ISSUED FOR OTHER THAN CASH

( us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock )

EARNINGS PER SHARE OF COMMON STOCK

EARNINGS PER SHARE OF COMMON STOCK

The Company had the following potential common stock equivalents at September 30, 2014:

Common stock warrants 5,500,000

Common stock options 105,000

Total common stock equivalents 5,605,000

The following table sets forth the computation of earnings per share:

	For the three months ended September 30, 2014	For the three months ended September 30, 2013	For the nine months ended September 30, 2014	For the nine months ended September 30, 2013
Net income (loss)	(1,579,095)	(829,135)	(4,891,557)	(2,252,058)
Weighted average common shares outstanding	58,005,199	52,234,857	56,776,286	51,706,494
Net (loss) per share	(.03)	(.02)	(.09)	(.04)

( us-gaap:EarningsPerSharePolicyTextBlock )

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT

The Company records property and equipment at cost and uses straight-line depreciation methods.

	Estimated Useful Lives	September 30, 2014	December 31, 2013
Computer equipment Office furniture	5 years 7 years	$ 11,634 4,746	$ 11,634 4,746

Less accumulated depreciation		(4,617)	(2,303)

Net property and equipment		$ 11,763	$ 14,077

( us-gaap:PropertyPlantAndEquipmentPolicyTextBlock )

ACCOUNTS RECEIVABLE

ACCOUNTS RECEIVABLE

( us-gaap:ReceivablesPolicyTextBlock )

INVENTORY

INVENTORY

	September 30, 2014	December 31, 2013
Inventories
Raw materials	$ 163,509	$ 26,903
Work in Process	52,615	-
Finished goods	23,630	-
Total Inventory	$ 239,754	$ 26,903

( us-gaap:InventoryPolicyTextBlock )

REVENUE RECOGNITION

Sales revenues are generally recognized when an agreement exists and price is determinable, the products are shipped to the customers, and allowance and collectability is reasonable assured.

( us-gaap:RevenueRecognitionPolicyTextBlock )

FOREIGN CURRENCY TRANSLATIONS

The Company recorded an unrealized foreign currency translation gain, totaling $0 for the period from January 23, 2007 (Inception) to September 30, 2014, in accumulated other comprehensive income.

( us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock )

CASH AND CASH EQUIVALENTS

CASH AND CASH EQUIVALENTS

Cash and cash equivalents consist of funds on deposit with banks. The Company has no cash equivalents. The Company had funds on deposit of $207,471 at September 30, 2014.

( us-gaap:CashAndCashEquivalentsPolicyTextBlock )

CONCENTRATION OF RISK

CONCENTRATION OF RISK

( us-gaap:FairValueConcentrationOfRiskTextBlock )

(End Disclosure - Significant Accounting Policies (Policies))

Disclosure - Significant Accounting Policies (Tables)

Disclosure - Significant Accounting Policies (Tables) (USD $)

9 Months Ended

( AccountingPoliciesAbstract )

Sep. 30, 2014

Computation of Earnings Per Share

	For the three months ended September 30, 2014	For the three months ended September 30, 2013	For the nine months ended September 30, 2014	For the nine months ended September 30, 2013
Net income (loss)	(1,579,095)	(829,135)	(4,891,557)	(2,252,058)
Weighted average common shares outstanding	58,005,199	52,234,857	56,776,286	51,706,494
Net (loss) per share	(.03)	(.02)	(.09)	(.04)

( us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock )

Schedule of Inventory Values

	September 30, 2014	December 31, 2013
Inventories
Raw materials	$ 163,509	$ 26,903
Work in Process	52,615	-
Finished goods	23,630	-
Total Inventory	$ 239,754	$ 26,903

( us-gaap:ScheduleOfInventoryCurrentTableTextBlock )

(End Disclosure - Significant Accounting Policies (Tables))

Disclosure - Going Concern and Liquidity Considerations (Details Narrative)

Disclosure - Going Concern and Liquidity Considerations (Details Narrative) (USD $)
( OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract )
	Sep. 30, 2014



Accumulated Deficit	13,133,804
( us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1 )

(End Disclosure - Going Concern and Liquidity Considerations (Details Narrative))

Disclosure - Provision for Income Taxes (Details Narrative)

Disclosure - Provision for Income Taxes (Details Narrative) (USD $)
( IncomeTaxDisclosureAbstract )
	Sep. 30, 2014



Operating Loss Carry-Forward	13,030,322
( us-gaap:DeferredTaxAssetsOperatingLossCarryforwards )
Deferred tax assets	5,502,973
( us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent )

(End Disclosure - Provision for Income Taxes (Details Narrative))

Contexts

ID	Period	CIK
From2014-01-01to2014-09-30	2014-01-01 - 2014-09-30	0001405249
AsOf2014-10-08	2014-10-08	0001405249
AsOf2014-09-30	2014-09-30	0001405249
AsOf2013-12-31	2013-12-31	0001405249
From2014-07-01to2014-09-30	2014-07-01 - 2014-09-30	0001405249
From2013-07-01to2013-09-30	2013-07-01 - 2013-09-30	0001405249
From2013-01-01to2013-09-30	2013-01-01 - 2013-09-30	0001405249
From2007-01-23to2014-09-30	2007-01-23 - 2014-09-30	0001405249
AsOf2012-12-31	2012-12-31	0001405249
AsOf2013-09-30	2013-09-30	0001405249
AsOf2007-01-22	2007-01-22	0001405249

(End Contexts)

Elements

Element		Data Type

AccountingPoliciesAbstract		xbrli:stringItemType	Duration	—

CompensationAndRetirementDisclosureAbstract		xbrli:stringItemType	Duration	—

DebtDisclosureAbstract		xbrli:stringItemType	Duration	—

EquityAbstract		xbrli:stringItemType	Duration	—

HealthCareOrganizationsAbstract		xbrli:stringItemType	Duration	—

IncomeTaxDisclosureAbstract		xbrli:stringItemType	Duration	—

OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract		xbrli:stringItemType	Duration	—

SubsequentEventsAbstract		xbrli:stringItemType	Duration	—

custom:DocumentAndEntityInformationAbstract		xbrli:stringItemType	Duration	—	Yes (Auto)

dei:AmendmentFlag		xbrli:booleanItemType	Duration	—
	If the value is true, then the document is an amendment to previously-filed/accepted document.
dei:CurrentFiscalYearEndDate		xbrli:gMonthDayItemType	Duration	—
	End date of current fiscal year in the format --MM-DD.
dei:DocumentFiscalPeriodFocus		dei:fiscalPeriodItemType	Duration	—
	This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
dei:DocumentFiscalYearFocus		xbrli:gYearItemType	Duration	—
	This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
dei:DocumentPeriodEndDate		xbrli:dateItemType	Duration	—
	The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
dei:DocumentType		dei:submissionTypeItemType	Duration	—
	The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
dei:EntityCentralIndexKey		dei:centralIndexKeyItemType	Duration	—
	A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
dei:EntityCommonStockSharesOutstanding		xbrli:sharesItemType	Instant	—
	Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
dei:EntityCurrentReportingStatus		dei:yesNoItemType	Duration	—
	Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
dei:EntityFilerCategory		dei:filerCategoryItemType	Duration	—
	Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
dei:EntityPublicFloat		xbrli:monetaryItemType	Instant	Credit
	State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.
dei:EntityRegistrantName		xbrli:normalizedStringItemType	Duration	—
	The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
dei:EntityVoluntaryFilers		dei:yesNoItemType	Duration	—
	Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
dei:EntityWellKnownSeasonedIssuer		dei:yesNoItemType	Duration	—
	Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
us-gaap:AccountsPayableCurrent		xbrli:monetaryItemType	Instant	Credit
	Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
us-gaap:AccountsReceivableNet		xbrli:monetaryItemType	Instant	Debit
	For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
us-gaap:AccruedLiabilitiesCurrent		xbrli:monetaryItemType	Instant	Credit
	Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
us-gaap:AccruedLiabilitiesCurrentAndNoncurrent		xbrli:monetaryItemType	Instant	Credit
	Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.
us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment		xbrli:monetaryItemType	Instant	Credit
	Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1		xbrli:monetaryItemType	Instant	Credit
	Amount before tax of increase (decrease) in accumulated in equity from transactions and other events and circumstances from non-owner sources. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).
us-gaap:AdditionalPaidInCapital		xbrli:monetaryItemType	Instant	Credit
	Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities		xbrli:monetaryItemType	Duration	Debit
	The aggregate amount of adjustments to net income or loss necessary to remove the effects of all items whose cash effects are investing or financing cash flows. The aggregate amount also includes all noncash expenses and income items which reduce or increase net income and are thus added back or deducted when calculating cash provided by or used in operating activities.
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature		xbrli:monetaryItemType	Duration	Credit
	Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt		xbrli:monetaryItemType	Duration	Credit
	Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.
us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract		xbrli:stringItemType	Duration	—

us-gaap:Assets		xbrli:monetaryItemType	Instant	Debit
	Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
us-gaap:AssetsAbstract		xbrli:stringItemType	Duration	—

us-gaap:AssetsCurrent		xbrli:monetaryItemType	Instant	Debit
	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
us-gaap:AssetsCurrentAbstract		xbrli:stringItemType	Duration	—

us-gaap:BasisOfAccounting		nonnum:textBlockItemType	Duration	—
	The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
us-gaap:BusinessAndContractualArrangementsDisclosureTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for prepaid health care service provider's significant business and contractual arrangements with hospitals, physicians, or other associated entities.
us-gaap:Cash		xbrli:monetaryItemType	Instant	Debit
	Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
us-gaap:CashAndCashEquivalentsAtCarryingValue		xbrli:monetaryItemType	Instant	Debit
	Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease		xbrli:monetaryItemType	Duration	Debit
	Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
us-gaap:CashAndCashEquivalentsPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
us-gaap:CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract		xbrli:stringItemType	Duration	—

us-gaap:CommonStockParOrStatedValuePerShare		num:perShareItemType	Instant	—
	Face amount or stated value per share of common stock.
us-gaap:CommonStockSharesAuthorized		xbrli:sharesItemType	Instant	—
	The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
us-gaap:CommonStockSharesIssued		xbrli:sharesItemType	Instant	—
	Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
us-gaap:CompensationAndEmployeeBenefitPlansTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.
us-gaap:ComprehensiveIncomeNetOfTax		xbrli:monetaryItemType	Duration	Credit
	Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
us-gaap:ConsolidationPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
us-gaap:CostOfGoodsSold		xbrli:monetaryItemType	Duration	Debit
	Total costs related to goods produced and sold during the reporting period.
us-gaap:DebtDisclosureTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent		xbrli:monetaryItemType	Instant	Debit
	Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed within one year or normal operating cycle, if longer.
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards		xbrli:monetaryItemType	Instant	Debit
	Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
us-gaap:Deposits		xbrli:monetaryItemType	Instant	Credit
	The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.
us-gaap:Depreciation		xbrli:monetaryItemType	Duration	Debit
	The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
us-gaap:DepreciationAndAmortization		xbrli:monetaryItemType	Duration	Debit
	The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage		xbrli:monetaryItemType	Instant	Debit
	Cumulative net losses reported during the development stage.
us-gaap:DevelopmentStageEnterpriseGeneralDisclosuresTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for all or part of the detailed information required for development stage enterprises. The information may also be disclosed on an element-by-element basis. Information may include an identification of the current or prior year financial statements of the entity, its development stage subsidiaries, or its investees as those of one or more development stage enterprises; a description of the nature of the development stage activities in which each enterprise is engaged; and in the first fiscal year in which each enterprise is no longer considered a development stage enterprise, a statement that in prior years the enterprise had been in the development stage.
us-gaap:EarningsPerSharePolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
us-gaap:ExplorationCosts		xbrli:monetaryItemType	Duration	Debit
	The capitalized costs incurred during the period (excluded from amortization) in identifying areas that may warrant examination and in examining specific areas that are considered to have prospects of containing oil and gas reserves, including costs of drilling exploratory wells and exploratory-type stratigraphic test wells. Exploration costs may be incurred both before acquiring the related property (sometimes referred to in part as prospecting costs) and after acquiring the property. Principal types of exploration costs, which include depreciation and applicable operating costs of support equipment and facilities and other costs of exploration activities, are: costs of topographical, geographical and geophysical studies, rights of access to properties to conduct those studies, and salaries and other expenses of geologists, geophysical crews, and others conducting those studies. Collectively, these are sometimes referred to as geological and geophysical or "G&G" costs. Exploration costs also include costs o
us-gaap:FairValueConcentrationOfRiskTextBlock		nonnum:textBlockItemType	Duration	—
	Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's acc
us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
us-gaap:GrossProfit		xbrli:monetaryItemType	Duration	Credit
	Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare		num:perShareItemType	Duration	—
	The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.
us-gaap:IncomeStatementAbstract		xbrli:stringItemType	Duration	—

us-gaap:IncomeTaxDisclosureTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
us-gaap:IncomeTaxExpenseBenefit		xbrli:monetaryItemType	Duration	Debit
	Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
us-gaap:IncreaseDecreaseInAccountsPayable		xbrli:monetaryItemType	Duration	Debit
	The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties		xbrli:monetaryItemType	Duration	Debit
	The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.
us-gaap:IncreaseDecreaseInAccountsReceivable		xbrli:monetaryItemType	Duration	Credit
	The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
us-gaap:IncreaseDecreaseInDeposits		xbrli:monetaryItemType	Duration	Debit
	The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances.
us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities		xbrli:monetaryItemType	Duration	Debit
	The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.
us-gaap:IncreaseDecreaseInInventories		xbrli:monetaryItemType	Duration	Credit
	The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
us-gaap:IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract		xbrli:stringItemType	Duration	—

us-gaap:IncreaseDecreaseInPrepaidExpense		xbrli:monetaryItemType	Duration	Credit
	The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
us-gaap:InterestAndDividendIncomeOperating		xbrli:monetaryItemType	Duration	Credit
	Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.
us-gaap:InventoryGross		xbrli:monetaryItemType	Instant	Debit
	Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
us-gaap:InventoryPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.
us-gaap:LiabilitiesAndStockholdersEquity		xbrli:monetaryItemType	Instant	Credit
	Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
us-gaap:LiabilitiesAndStockholdersEquityAbstract		xbrli:stringItemType	Duration	—

us-gaap:LiabilitiesCurrent		xbrli:monetaryItemType	Instant	Credit
	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
us-gaap:LiabilitiesCurrentAbstract		xbrli:stringItemType	Duration	—

us-gaap:LiquidityDisclosureTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substa
us-gaap:LongTermDebtAbstract		xbrli:stringItemType	Duration	—

us-gaap:LongTermDebtNoncurrent		xbrli:monetaryItemType	Instant	Credit
	Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
us-gaap:LongTermDebtTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for long-term debt.
us-gaap:NetCashProvidedByUsedInContinuingOperations		xbrli:monetaryItemType	Duration	—
	The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.
us-gaap:NetCashProvidedByUsedInFinancingActivities		xbrli:monetaryItemType	Duration	Debit
	Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
us-gaap:NetCashProvidedByUsedInFinancingActivitiesAbstract		xbrli:stringItemType	Duration	—

us-gaap:NetCashProvidedByUsedInInvestingActivities		xbrli:monetaryItemType	Duration	Debit
	Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
us-gaap:NetCashProvidedByUsedInInvestingActivitiesAbstract		xbrli:stringItemType	Duration	—

us-gaap:NetCashProvidedByUsedInOperatingActivitiesAbstract		xbrli:stringItemType	Duration	—

us-gaap:NetIncomeLoss		xbrli:monetaryItemType	Duration	Credit
	The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic		xbrli:monetaryItemType	Duration	Credit
	Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).
us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
us-gaap:NotesPayable		xbrli:monetaryItemType	Instant	Credit
	Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
us-gaap:OperatingExpensesAbstract		xbrli:stringItemType	Duration	—

us-gaap:OperatingIncomeLoss		xbrli:monetaryItemType	Duration	Credit
	The net result for the period of deducting operating expenses from operating revenues.
us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
us-gaap:OtherAssets		xbrli:monetaryItemType	Instant	Debit
	The aggregate carrying amounts, as of the balance sheet date, of assets not separately disclosed in the balance sheet.
us-gaap:OtherAssetsAbstract		xbrli:stringItemType	Duration	—

us-gaap:OtherIncomeAndExpensesAbstract		xbrli:stringItemType	Duration	—

us-gaap:OtherNoncashIncomeExpense		xbrli:monetaryItemType	Duration	Credit
	Other income (expense) included in net income that results in no cash inflows or outflows in the period. Includes noncash adjustments to reconcile net income (loss) to cash provided by (used in) operating activities that are not separately disclosed.
us-gaap:PaymentsOfStockIssuanceCosts		xbrli:monetaryItemType	Duration	Credit
	The cash outflow for cost incurred directly with the issuance of an equity security.
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment		xbrli:monetaryItemType	Duration	Credit
	The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
us-gaap:PrepaidExpenseCurrent		xbrli:monetaryItemType	Instant	Debit
	Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
us-gaap:ProceedsFromIssuanceOrSaleOfEquity		xbrli:monetaryItemType	Duration	Debit
	The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
us-gaap:ProceedsFromNotesPayable		xbrli:monetaryItemType	Duration	Debit
	The cash inflow from a borrowing supported by a written promise to pay an obligation.
us-gaap:PropertyPlantAndEquipmentAbstract		xbrli:stringItemType	Duration	—

us-gaap:PropertyPlantAndEquipmentDisposals		xbrli:monetaryItemType	Duration	Credit
	Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
us-gaap:PropertyPlantAndEquipmentNet		xbrli:monetaryItemType	Instant	Debit
	Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
us-gaap:PropertyPlantAndEquipmentOther		xbrli:monetaryItemType	Instant	Debit
	Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.
us-gaap:PropertyPlantAndEquipmentPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
us-gaap:ReceivablesPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.
us-gaap:RepaymentsOfConvertibleDebt		xbrli:monetaryItemType	Duration	Credit
	The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
us-gaap:ResearchAndDevelopmentExpense		xbrli:monetaryItemType	Duration	Debit
	The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
us-gaap:RevenueRecognitionPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
us-gaap:Revenues		xbrli:monetaryItemType	Duration	Credit
	Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock		nonnum:textBlockItemType	Duration	—
	Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
us-gaap:ScheduleOfInventoryCurrentTableTextBlock		nonnum:textBlockItemType	Duration	—
	Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
us-gaap:SellingGeneralAndAdministrativeExpense		xbrli:monetaryItemType	Duration	Debit
	The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for accounts comprising shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income, and compensation-related costs for equity-based compensation. Includes, but is not limited to, disclosure of policies, compensation plan details, equity-based arrangements to obtain goods and services, deferred compensation arrangements, and employee stock purchase plan details.
us-gaap:SignificantAccountingPoliciesTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for all significant accounting policies of the reporting entity.
us-gaap:StatementOfCashFlowsAbstract		xbrli:stringItemType	Duration	—

us-gaap:StatementOfFinancialPositionAbstract		xbrli:stringItemType	Duration	—

us-gaap:StockholdersEquity		xbrli:monetaryItemType	Instant	Credit
	Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
us-gaap:StockholdersEquityAbstract		xbrli:stringItemType	Duration	—

us-gaap:StockholdersEquityNoteDisclosureTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
us-gaap:SubsequentEventsTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
us-gaap:UseOfEstimates		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
us-gaap:WeightedAverageBasicSharesOutstandingProForma		xbrli:sharesItemType	Duration	—
	The weighted average number of shares (units) outstanding in the calculation of pro forma basic earnings per share (earnings per unit), which is commonly presented in initial public offerings based on the terms of the offering.
Total Elements					133
Total Non-Abstract Elements					105
Total Extension Elements					1
Percent Extended					0%
Percent Extended (excluding abstracts)					0%

(End Elements)